Friday, April 4, 2025 4/4/2025

Role of Methionine Sulfoxide and Advanced Glycation Endproducts in Cardiovascular and Renal Complications of Type 2 Diabetes

Award Number: R21HL150268
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Role of Methionine Sulfoxide and Advanced Glycation Endproducts in Cardiovascular and Renal Complications of Type 2 Diabetes - Abstract Oxidative end-products (OxPs) and advanced glycation end-products (AGEs) are long-lived reactive intermediates formed by reactions of reactive oxygen species and chemically reactive sugars with proteins, lipids and nucleic acids. Both are increased in diabetes and are believed to be important contributors to both micro- and macrovascular complications of diabetes. Several clinical and epidemiological studies indicated an association between selective individual AGE/OxPs in blood and cardiovascular risk. However, studies were often small, cross-sectional, used a single AGE or OxP or relatively inaccurate immunoassays, so convincing human data are lacking. A novel high-throughput LC-triple quadrupole approach has been recently developed to measure a panel of AGEs and OxPs concentrations in blood that is comprehensive, precise and can be readily applied to large sample numbers. Using this highly accurate technique, we demonstrated that several baseline plasma AGEs and OxPs (and combinations of them) from the panel were positively associated with long-term progression of coronary and carotid atherosclerosis and with incident CVD in a subset of participants of the Veterans Affairs Diabetes Trial (VADT). Specifically, we found a strong negative association between plasma levels of one of the OxPs, Methionine Sulfoxide (MetSO) and incident CVD events suggesting this unique OxP may offer, or reflect, protection against CVD. We observed many of the same CVD findings (including that for MetSO) in a small case- control subgroup of the Action to Control Cardiovascular Risk in Diabetes (ACCORD). None of the AGE/OxPs were related to concurrent hemoglobin A1c (HbA1c) levels but instead were associated with diabetes duration, consistent with long-term effects of hyperglycemia on these compounds. Furthermore, higher AGEs strongly predicted progression of diabetes kidney disease in our VADT subset, independently of glycemic control and other traditional risk factors of renal disease. These data were consistent previous small studies highlighting that several AGEs were related to renal pathology and its progression in type 2 diabetes. The present proposal builds on these findings and investigates the relationships of MetSO and AGEs and OxPs with diabetes complications diabetes complications in a case-cohort sample of the ACCORD trial. In Aim 1 we propose to validate an inverse relationship between MetSO and CVD. We will test whether baseline MetSO levels are associated with incident CVD events. We will also explore the relationship between individual AGEs or combined OxP/AGE scores and incident CVD, and whether a combined MetSO/AGE improve CVD risk prediction models. In Aim 2 we will determine whether AGEs are associated with incident diabetes kidney disease (DKD). We will explore whether individual AGEs or combined AGE scores would improve DKD prediction models. This first large scale and comprehensive evaluation will greatly expand our understanding of the relationships between AGE/OxPs and diabetes complications and their importance in humans, and potentially improve our risk assessment and discrimination models.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$19,219 )
2024	2020	ARIZONA VETERANS RESEARCH AND EDUCATION FOUNDATION	650 E INDIAN SCHOOL RD # RS151B	PHOENIX	AZ	85012	MARICOPA	USA	Cardiovascular Diseases Research	000	2	10/17/2023	NON-COMPETING CONTINUATION	-$19,219
														Subtotal = -$19,219

Issue Date FY: 2020 ( Subtotal = $106,147 )
2020	2020	CARL T. HAYDEN MEDICAL RESEARCH FOUNDATION	650 E INDIAN SCHOOL RD	PHOENIX	AZ	85012	MARICOPA	USA	Cardiovascular Diseases Research	001	2	8/21/2020	NON-COMPETING CONTINUATION	$106,147
2020	2019	CARL T. HAYDEN MEDICAL RESEARCH FOUNDATION	650 E INDIAN SCHOOL RD	PHOENIX	AZ	85012	MARICOPA	USA	Cardiovascular Diseases Research	000	1	3/19/2020	NEW	$0
														Subtotal = $106,147

Issue Date FY: 2019 ( Subtotal = $117,147 )
2019	2019	CARL T. HAYDEN MEDICAL RESEARCH FOUNDATION	650 E INDIAN SCHOOL RD	PHOENIX	AZ	85012	MARICOPA	USA	Cardiovascular Diseases Research	000	1	9/20/2019	NEW	$117,147
														Subtotal = $117,147

Grand Total All Awards = $204,075

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Role of Methionine Sulfoxide and Advanced Glycation Endproducts in Cardiovascular and Renal Complications of Type 2 Diabetes

Award Number: R21HL150268

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer